Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0V4WT
|
||||
| Former ID |
DIB020644
|
||||
| Drug Name |
paxilline
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C27H33NO4
|
||||
| InChI |
InChI=1S/C27H33NO4/c1-24(2,30)23-20(29)14-18-21(32-23)10-11-25(3)26(4)15(9-12-27(18,25)31)13-17-16-7-5-6-8-19(16)28-22(17)26/h5-8,14-15,21,23,28,30-31H,9-13H2,1-4H3
|
||||
| InChIKey |
ACNHBCIZLNNLRS-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Maxi K potassium channel | Target Info | Blocker (channel blocker) | [2] | |
| Oxysterols receptor LXR-alpha | Target Info | Agonist | [3] | ||
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Vascular smooth muscle contraction | |||||
| Insulin secretion | |||||
| Salivary secretion | |||||
| Pancreatic secretionhsa03320:PPAR signaling pathway | |||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Hepatitis C | |||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | ||||
| Reactome | cGMP effects | ||||
| WikiPathways | Potassium Channels | ||||
| Platelet homeostasisWP299:Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
| Nuclear Receptors Meta-Pathway | |||||
| PPAR Alpha Pathway | |||||
| Liver X Receptor Pathway | |||||
| Adipogenesis | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| Nuclear Receptors | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2309). | ||||
| REF 2 | Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel. Neuropharmacology. 1996;35(7):963-8. | ||||
| REF 3 | A natural product ligand of the oxysterol receptor, liver X receptor. J Pharmacol Exp Ther. 2003 Oct;307(1):291-6. Epub 2003 Jul 31. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.